CAMP
Camp4 Therapeutics Corp
Next earnings Aug 12, 2026 · consensus $-0.21 EPS, $1.93M rev
Last earnings +6.9% on 2026-05-07
$4.20
▲ +7.14%$4.20▲ +200.00%
over 1Y
L $1.35EODHDH $7.13
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+7.1%
1W+7.1%
1M-0.2%
3M-2.6%
YTD-30.0%
1Y+200.0%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 12 analysts
Buy
Revenue grew 436.5% YoY; but unprofitable (net margin -2298.5%).
Camp4 Therapeutics Corp shows $3.50M in FY2025 revenue (+436.5% YoY), a -2298.5% net margin, and -168.5% ROE.
Financials · annual, by fiscal year
| Line item | FY23 | FY24 | FY25 |
|---|---|---|---|
| Revenue | $350K | $652K | $3.50M |
| Gross profit | — | — | — |
| Operating income | -$51.9M | -$53.1M | -$52.6M |
| Net income | -$49.3M | -$51.8M | -$80.4M |
| Diluted EPS | -$124.80 | -$11.04 | -$2.65 |
| Net margin | -14083.1% | -7943.4% | -2298.5% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$109M
EV / EBITDA—
EV / Sales31.0
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-36.9%
FCF yield-13.7%
Quality & risk
ROIC (est.)-87.0%
Free cash flow-$29.8M
Total debt—
Net cash$110M
Altman Z-Score-2.04 distress
Piotroski F-Score3/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+157.5%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
- 8-K Officer / director change2026-06-12
- 8-K Reg FD disclosure2026-05-14
- 8-K Earnings results2026-05-07
- 10-Q Quarterly report2026-05-07
- DEF 14A Proxy statement2026-04-23
- 8-K Officer / director change2026-03-24
- 8-K Acquisition / disposition2026-03-05
- 10-K Annual report2026-03-05
- 8-K Reg FD disclosure2026-01-09
Recent filings
all on EDGAR ↗4Period ending 2026-06-102026-06-12open ↗4Period ending 2026-06-102026-06-12open ↗4Period ending 2026-06-102026-06-12open ↗4Period ending 2026-06-102026-06-12open ↗4Period ending 2026-06-102026-06-12open ↗4Period ending 2026-06-102026-06-12open ↗8-KPeriod ending 2026-06-102026-06-12open ↗SCHEDULE 13GFiling2026-05-15open ↗8-KPeriod ending 2026-05-142026-05-14open ↗10-QPeriod ending 2026-03-312026-05-07open ↗8-KPeriod ending 2026-05-072026-05-07open ↗ARSPeriod ending 2025-12-312026-04-23open ↗
Frequently asked
- Is Camp4 Therapeutics Corp (CAMP) a buy?
- CAMP currently carries a Sell rating with 2/5 conviction, derived from its latest SEC filings. Revenue grew 436.5% YoY; but unprofitable (net margin -2298.5%).
- What is Camp4 Therapeutics Corp's quality score?
- CAMP scores 38.09803921568627/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001736730, latest 10-Q filed 2026-05-07) · EODHD · as of 6/26/2026, 7:15:09 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.